Loading clinical trials...

Diffusion Basis Spectrum Imaging of the Prostate | Clinical Trials | Clareo Health

RECRUITINGNA

Diffusion Basis Spectrum Imaging of the Prostate

Diffusion Basis Spectrum Imaging of the Prostate: A Virtual Biopsy to Accurately Diagnose Prostate Cancer

NCT04420702•Washington University School of Medicine

Summary

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Over 18 years of age and willing and able to provide informed consent.
•Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
•Including those men with:
•* an elevated PSA and no prior biopsy
•* an elevated PSA and a negative prior biopsy
•Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion Criteria

•Patients with any clinical contraindication to MRI
•\*Including but not limited to:
•* Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
•* Those with cochlear implants
•* Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
•* Those who cannot lie flat for over 1 hour
•Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

February 27, 2020

Primary Completion Date

May 31, 2027

Completion Date

May 31, 2027

Last Updated

July 18, 2025

Enrollment

500

ESTIMATED participants

Conditions

Prostate Cancer

Interventions

MRI with DBSI analysis

DEVICE

Contacts

Joseph Ippolito, M.D.

CONTACT

314-362-2925 ippolitoj@wustl.edu

Alex Klim

CONTACT

314-747-9781 klima@wustl.edu

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diffusion Basis Spectrum Imaging of the Prostate

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC